Imitrex Articles
FDA OKs Merz' Xeomin for cervical dystonia and blepharospasm; and two generics for Sagent
3 August 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
Big upside for Ranbaxy as it launches generic version of Glaxos herpes drug Valtrex
27 November 2009
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
US FDA approves Ranbaxy’s generic sumatriptan
11 August 2009
Dr Reddy's falls to loss on goodwill adjustment
1 June 2009
Stock Commentary - New York week to March 30, 2009
2 April 2009
US FDA clears Teva's generic Imitrex
16 February 2009
USA's Consumer Reports warns pain pills can worsen headaches
8 September 2008
GSK's Treximet receives FDA approval
21 April 2008
Rx-to-OTC switching making comeback
21 April 2008
Generic settlements over Exelon and Imitrex
28 January 2008
Tonabersat falls short in migraine trial
15 January 2007
Pozen submits full Trexima response to FDA
20 November 2006
Spectrum/Par settle with GSK
20 November 2006
Dr Reddy's settles patent row with GSK
23 October 2006
Early Trexima use cuts migraine symptoms
2 October 2006
FDA delays decision on Pozen/GSK's Trexima
19 June 2006
Allergan reports strong 4th-qtr results
13 February 2006
Ranbaxy Pharma gets tentative FDA nod for sumatriptan
8 August 2005
FDA accepts Spectrum's ANDA for cancer drug
1 August 2005
Euro patent for Pozen's migraine drug
31 January 2005
US ANDA filings "buy time for branded drugs"
24 January 2005
FDA accepts Spectrum's sumatriptan ANDA
17 January 2005
New form of GSK's Imigran provides fast relief of migraine
27 September 2004
Ranbaxy 5th largest generics firm in France
5 January 2004
FDA rejects Pozen's lead migraine product
27 October 2003
Pozen files NDA in the USA for MT 100
11 August 2003
Aradigm acquires Weston Intraject technology
19 May 2003
Pfizer takes on India's Ranbaxy over Lipitor
3 March 2003
AlgoRx licenses novel triptan formulation for migraine
17 February 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
AstraZeneca's Zomig nasal spray gets first launch in Sweden
25 February 2002
Galapagos Genomics and Euroscreen sign GPCR deal
12 December 2001
Pharmacia gets US approval for Axert
9 May 2001
Almogran set for German launch soon?
6 March 2001
World migraine therapy sales to 2009
14 November 2000
Elan's migraine drug nears US approval
4 May 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
Glaxo Wellcome Jan-Oct trading results see sales up 6%
17 November 1999
FDA requests drug interaction data for Pfizer's Relpax
26 October 1999
Lilly pulls plug on migraine drug
29 March 1999
Future growth of the global pharmaceutical market evaluated by MSDW
23 February 1999
Vanguard Medica files Miguard NDA
2 February 1999
Merck's Maxalt Approved In USA
1 July 1998
Naratriptan Launched In The USA
26 March 1998
Merck & Co's Rizatriptan Approved In Holland
25 February 1998
GW's Naratriptan Approved In The USA
12 February 1998
Migraine Market Hotting Up In The USA
20 January 1998
News In Brief
11 December 1997
GW's Nasal Spray Is Launched
4 December 1997
US DTC Advertising Is Fastest Growing Promotional Segment
21 October 1997
GW's Imitrex Approved In USA
4 September 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
US Rx Drug Sales For 1996 Up 10% At $85.35 Billion
24 February 1997
Correction in GW share Price An Over-reaction?
22 April 1996
Zantac Sales Slide 4% At Glaxo Wellcome
11 March 1996
GW Licenses Migraine Drug To Zeneca
19 February 1996
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
Glaxo Wellcome Reveals Integration Effects
11 September 1995
Glaxo Wellcome's oral Imitrex
14 August 1995
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
Merck pipline report
3 July 1995
Glaxo Wellcome's Imitrex appproved
19 June 1995
Vanguard Medica: A Development Specialist
29 May 1995
European Stock Comment
17 April 1995
Oral Imitrex Approvable In USA
10 April 1995
Glaxo Interim Profits Up 10% On 2% Sales Rise
13 February 1995
Glaxo Wellcome: Consolidatory But No Panacea
30 January 1995
European Stock Comment
28 November 1994
Glaxo Expands Imitrex Warnings
21 November 1994
Glaxo's Pipeline Update As Expected
19 September 1994
Competition and Acquisition Pressure Hits Glaxo
19 September 1994
Imitrex To Have Warnings In USA
5 September 1994
CNS DISORDERS IN THE COMING DECADE
16 May 1994
GERMAN RANITIDINE PATENT DISPUTE DELAYED
7 February 1994
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
